Cart
sales@molnova.com
Moxnidazole
CAS No. 52279-59-1
Moxnidazole( —— )
Catalog No. M36201 CAS No. 52279-59-1
Moxnidazole, a 5-nitroimidazole, is mutagenic in microbial assays and in Drosophila, inducing genetic alterations in mouse somatic cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 187 | In Stock |
|
| 10MG | 275 | In Stock |
|
| 25MG | 430 | In Stock |
|
| 50MG | 600 | In Stock |
|
| 100MG | 820 | In Stock |
|
| 200MG | 1097 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMoxnidazole
-
NoteResearch use only, not for human use.
-
Brief DescriptionMoxnidazole, a 5-nitroimidazole, is mutagenic in microbial assays and in Drosophila, inducing genetic alterations in mouse somatic cells.
-
DescriptionMoxnidazole, a 5-nitroimidazole, is mutagenic in microbial assays and in Drosophila, inducing genetic alterations in mouse somatic cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number52279-59-1
-
Formula Weight338.32
-
Molecular FormulaC13H18N6O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(=CC=1N(C)C(N(=O)=O)=CN1)N2CC(CN3CCOCC3)OC2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
1-(4-Carbethoxypheny...
1-(4-Carbethoxyphenyl)-piperazin is a chemical compound.
-
FIDAS-5
FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.
-
Mitazalimab
Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that targets tumors by activating antigen-presenting cells like dendritic cells (DC), initiating tumor-reactive T cells, promoting tumor-specific T cell infiltration and destruction of tumors, and remodeling the tumor-infiltrating myeloid microenvironment .
